
Diaceutics PLC – LSE:DXRX.L
Diaceutics stock price today
Diaceutics stock price monthly change
Diaceutics stock price quarterly change
Diaceutics stock price yearly change
Diaceutics key metrics
Market Cap | 104.36M |
Enterprise value | 6.35B |
P/E | 139.65 |
EV/Sales | 501.46 |
EV/EBITDA | 5898.45 |
Price/Sales | 5.02 |
Price/Book | 1.55 |
PEG ratio | 1.24 |
EPS | -0.01 |
Revenue | 43.20M |
EBITDA | 5.16M |
Income | -1.02M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 3.6% |
Oper. margin | 15.13% |
Gross margin | 74.43% |
EBIT margin | 15.13% |
EBITDA margin | 11.95% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDiaceutics stock price history
Diaceutics stock forecast
Diaceutics financial statements
Jun 2022 | 7.52M | -767K | -10.19% |
---|---|---|---|
Dec 2022 | 11.97M | 1.49M | 12.45% |
Jun 2023 | 9.92M | -1.48M | -14.96% |
Dec 2023 | 13.77M | -261K | -1.89% |
2027 | 58.17M | 7.48M | 12.87% |
---|
Analysts Price target
Financials & Ratios estimates
Jun 2022 | 45528000 | 4.57M | 10.06% |
---|---|---|---|
Dec 2022 | 48256000 | 5.74M | 11.9% |
Jun 2023 | 46121000 | 5.06M | 10.98% |
Dec 2023 | 46344000 | 5.55M | 11.99% |
Jun 2022 | 3.26M | -2.38M | -45K |
---|---|---|---|
Dec 2022 | 1.88M | -2.49M | -87K |
Jun 2023 | 951K | -2.94M | -141K |
Dec 2023 | 995K | -1.90M | -87K |
Diaceutics alternative data
Aug 2023 | 151 |
---|---|
Sep 2023 | 151 |
Oct 2023 | 151 |
Nov 2023 | 151 |
Dec 2023 | 151 |
Jan 2024 | 151 |
Feb 2024 | 151 |
Mar 2024 | 151 |
Apr 2024 | 151 |
May 2024 | 151 |
Jun 2024 | 151 |
Jul 2024 | 184 |
Diaceutics other data
-
What's the price of Diaceutics stock today?
One share of Diaceutics stock can currently be purchased for approximately $102.
-
When is Diaceutics's next earnings date?
Unfortunately, Diaceutics's (DXRX.L) next earnings date is currently unknown.
-
Does Diaceutics pay dividends?
No, Diaceutics does not pay dividends.
-
How much money does Diaceutics make?
Diaceutics has a market capitalization of 104.36M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 21.51% to 23.7M US dollars.
-
What is Diaceutics's stock symbol?
Diaceutics PLC is traded on the LSE under the ticker symbol "DXRX.L".
-
What is Diaceutics's primary industry?
Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.
-
How do i buy shares of Diaceutics?
Shares of Diaceutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Diaceutics have?
As Jul 2024, Diaceutics employs 184 workers, which is 22% more then previous month and 22% more then previous quarter.
-
When Diaceutics went public?
Diaceutics PLC is publicly traded company for more then 6 years since IPO on 21 Mar 2019.
-
What is Diaceutics's official website?
The official website for Diaceutics is diaceutics.com.
Diaceutics company profile:

Diaceutics PLC
diaceutics.comLSE
184
Medical - Diagnostics & Research
Healthcare
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
Belfast, BT9 6GW
:
ISIN: GB00BJQTGV64
CUSIP: G2755U109